Assessing the Ethics of the Dominant Business Model in the Canadian Pharmaceutical Sector; Tackling Institutional Corruption through Regulatory Reforms

评估加拿大制药行业主导商业模式的道德规范；

• 批准号: 255847
• 负责人: Gagnon Marc-Andr
• 金额: $ 6.13万
• 依托单位: Carleton University (Ottawa)
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2012
• 资助国家: 加拿大
• 起止时间: 2012-03-01 至 2014-03-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=255847&lang=en
• 关键词: Business Model; Cost And Prices Of Medicines; Ghostmanagement Of Medical Literature; Innovation Policies; Investment And Profitability; Off-Label Use; Pharmaceutical Promotion; Pharmaceutical Sector; Research Ethics; Therapeutic Innovation

Is the dominant business model of core pharmaceutical companies built on ethical foundations? Is the earning capacity of drug companies in line with the improvement of public health? In the last 15 years, fewer new drugs have arrived on the market, and th

核心制药公司的主导商业模式是否建立在道德基础之上？制药公司的盈利能力是否与公众健康的改善相一致？在过去的15年里，市场上的新药越来越少，